Naegleria fowleri, a brain-eating amoeba, is one of the most lethal infections in the world. Scientists at UC San Diego have isolated a molecule that could help us fight back.
Image Credit: Scientific Frontline / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Rutamycin B and Primary Amoebic Meningoencephalitis
The Core Concept: Rutamycin B is a potent marine-derived compound that demonstrates rapid and selective efficacy against Naegleria fowleri, the parasitic amoeba responsible for the highly lethal brain infection known as primary amoebic meningoencephalitis (PAM).
Key Distinction/Mechanism: While standard treatments like amphotericin B can be slow-acting and highly toxic, rutamycin B works by shutting down the parasite's energy-producing enzymes, reaching full potency in just four hours, and is 200 to 300 times more lethal to the amoeba than to human cells.
Origin/History: In October 2026, researchers at the University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and Scripps Institution of Oceanography published their discovery of the compound's efficacy in the journal Marine Drugs.
Major Frameworks/Components:
- Enzyme inhibition: The compound targets and neutralizes specific enzymes required for the parasite's energy production.
- Therapeutic synergy: When combined with standard treatments, rutamycin B achieves equivalent efficacy using only 3 to 10 percent of the original dose.
- Structural optimization: Researchers are currently focused on evaluating the compound's ability to cross the blood-brain barrier in live disease models.
Branch of Science: Pharmacology, Parasitology, Marine Biology, Neuroscience.
Future Application: This discovery provides a foundational framework for developing faster, less toxic therapies that could dramatically improve survival rates for PAM, while also highlighting the untapped potential of marine environments for novel drug discovery.
Why It Matters: With a fatality rate exceeding 97 percent, PAM progresses too rapidly for current therapies to succeed; identifying a fast-acting, highly selective compound like rutamycin B is crucial for stopping irreversible brain damage and offering a viable prognosis for patients with this historically fatal disease.
Primary amoebic meningoencephalitis (PAM), a parasitic disease that causes the rapid deterioration of brain tissue, is one of the most lethal infections known, with a fatality rate exceeding 97%. Caused by the free-living amoeba Naegleria fowleri (N. fowleri), the disease progresses with devastating speed, often leaving patients with only a few days to respond to treatment. Now, researchers at the University of California San Diego have isolated a marine-derived compound that may provide a faster, more effective way to stop the parasite in its tracks.
The researchers report that rutamycin B—a compound isolated from a marine bacterium—demonstrates significant potency at low concentrations against multiple clinical strains of N. fowleri. Most notably, the compound achieves full potency within just four hours, significantly outpacing amphotericin B, the current gold-standard treatment.
“Current treatments for PAM often act too slowly or carry heavy toxicity,” said Anjan Debnath, PhD, associate professor at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and co-director of UC San Diego’s Center for Discovery and Innovation in Parasitic Diseases. “By identifying a compound that is both faster and more selective, we are moving closer to a treatment that can stop the infection before it causes irreversible damage, which could fundamentally change the prognosis for people who contract this parasite.”
The findings also speak to the therapeutic potential of compounds isolated from the ocean.
“The ocean contains a diverse library of chemicals, and we’ve only just scratched its surface,” said William Fenical, PhD, distinguished professor emeritus at UC San Diego’s Scripps Institution of Oceanography. “These results are a powerful reminder that the solutions to some of our most challenging medical problems may be hiding in unexpected places.”
Beyond its immediate potency, the team believes the structural properties of rutamycin B make it a promising candidate for further pharmacological optimization. Because the infection targets the central nervous system, the researchers are planning future studies to evaluate the compound's ability to cross the blood-brain barrier and its efficacy in live disease models.
While further research will be needed to bring this approach into the clinic, the study points toward a promising new therapeutic strategy for a disease that has historically left almost no survivors.
Funding: The study was funded in part by grants from the National Institutes of Health (R21EY034294 and R21AI171538). An International Application (PCT)
Published in journal: Marine Drugs
Title: Antiamoebic Activity of Rutamycin B and Inhibition of Naegleria fowleri F1FO ATP Synthase Activity
Authors: Hayley Fong, Elkay Galang, Reiko Iizumi, William Fenical, and Anjan Debnath
Source/Credit: University of California San Diego | Miles Martin
Edited by: Scientific Frontline
Reference Number: pharm102626_01